Clinical Trial Update: Entrectinib in Combination With ASTX727 for the Treatment of Relapsed/Refractory TP53 Mutated Acute Myeloid Leukemia [Phase 1]

View source ↗

Summary

Phase 1 trial update for entrectinib in combination with ASTX727 in relapsed/refractory TP53-mutated acute myeloid leukemia; the study is currently active and n…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• ASTX727 (cedazuridine/decitabine)
• Rozlytrek (entrectinib) (entrectinib)

Snippet

Sponsor: OHSU Knight Cancer Institute | Conditions: Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia | Phase 1 | Status: ACTIVE_NOT_RECRUITING